SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.

Umang Swami Ryon P Graf Roberto H Nussenzveig Virginia A Fisher Hanna Tukachinsky Alexa B Schrock Gerald Li Jeffery S Ross Nicolas Sayegh Nishita Tripathi Vinay M Thomas Geoffrey R Oxnard Emmanuel S Antonarakis Archana M Agarwal

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

In real-world settings, SPOP mutations were associated with improved outcomes to ADT plus ARAT (but not ADT plus docetaxel) in patients with dn-mCSPC. This may serve as a predictive biomarker to guide treatment selection for patients with mCSPC.

Keyphrases

prostate cancer
small cell lung cancer
squamous cell carcinoma
radical prostatectomy
combination therapy
radiation therapy